Core Viewpoint - The stock price of Gaoshi Medical (02407) has experienced fluctuations following its removal from the Hong Kong Stock Connect list, with a significant increase in the first half of the year, but a subsequent decline of nearly 20% since December 22, raising questions about its upcoming performance in the 2025 annual report [1][2][7]. Group 1: Stock Performance - Gaoshi Medical's stock price rose by 65.50% from May to September last year, despite being removed from the Hong Kong Stock Connect list in March [1]. - Following a peak, the stock entered a three-month period of consolidation before declining after December [1]. - The stock has seen a cumulative decline of nearly 20% since December 22, effectively reversing all gains made since the mid-year report [1]. Group 2: Hong Kong Stock Connect Impact - On March 10, the adjustment of the Hong Kong Stock Connect list led to an average stock price drop of 14.24% for excluded stocks, with Gaoshi Medical being one of the affected companies [1]. - Despite the stock's removal, the proportion of shares held by Hong Kong Stock Connect investors decreased only slightly from 6.85% to 3.85% over ten months, indicating limited selling pressure [2]. Group 3: Trading Volume and Liquidity - Post-removal, the trading volume of Gaoshi Medical's shares significantly decreased, with a drop of 84.39% in monthly trading volume from February to April compared to the previous period [4]. - By December, the monthly trading volume had further declined to just 97.35 million shares [4]. Group 4: Financial Performance - In 2024, Gaoshi Medical reported revenues of 1.428 billion yuan, a year-on-year increase of 1.6%, but a 4.1% decrease in gross profit to 663 million yuan, with net profit down 46.75% to 92.39 million yuan [7]. - The decline in profitability was attributed to factors such as exchange rate fluctuations and the implementation of national procurement policies for artificial crystals, alongside goodwill impairment totaling 23.26 million yuan [7]. Group 5: Business Strategy and Future Outlook - Gaoshi Medical is attempting to adjust its business structure by increasing the proportion of self-owned products, although the revenue share from distribution products increased to 68.55% in 2024 [8]. - The company reported a significant improvement in its financials for the first half of 2025, with revenues of 653 million yuan, a 1.7% increase, and a net profit of 35.9 million yuan, up 33.5% [8]. - Analysts project revenue growth for 2025-2027, with expected revenues of 1.564 billion, 1.715 billion, and 1.875 billion yuan, and net profits of 135 million, 180 million, and 214 million yuan respectively [9].

Core Viewpoint - The company reported a strong financial performance for 2024, with significant year-on-year growth in revenue and net profit, indicating robust operational capabilities and effective cost management [1][2]. Financial Performance - For 2024, the company achieved revenue of 3.61 billion yuan, a year-on-year increase of 23.2%, and a net profit attributable to shareholders of 220 million yuan, up 130.7% [1]. - The fourth quarter alone saw revenue of 1.62 billion yuan, with net profit reaching 130 million yuan, reflecting a year-on-year growth of 28.9% and 253.4% respectively [1]. - The operating cash flow for the year was 290 million yuan, showing a slight increase of 0.6% year-on-year [1]. Industry Growth - The power industry revenue reached 1.86 billion yuan, growing by 5.6%, while other sectors saw a significant increase of 49.8% to 1.74 billion yuan [1]. - New strategic sectors, including oil and gas, nuclear industry, transportation, government emergency services, and power generation, generated 1.09 billion yuan in revenue, marking an 80.0% increase [1]. Sales Model Breakdown - Revenue from distribution products, self-developed products, and services amounted to 2.54 billion yuan, 670 million yuan, and 390 million yuan respectively, with year-on-year growth rates of 23.4%, 29.1%, and 12.9% [2]. Cost Management and Profitability - The overall gross margin for 2024 was 29.7%, a decrease of 2.5 percentage points, primarily due to lower margins from new high-growth sectors [2]. - The expense ratio improved to 19.4%, down 3.3 percentage points, with reductions in sales, management, and R&D expense ratios contributing to enhanced profitability [2]. - The net profit margin for the year was 6.6%, an increase of 2.9 percentage points year-on-year [2]. Q4 Performance Insights - In Q4, the gross margin was 31.8%, down 3.8 percentage points, while the expense ratio was 17.4%, a decrease of 4.6 percentage points [3]. - The net profit margin for Q4 was 8.6%, reflecting a year-on-year increase of 5.0 percentage points [3]. Future Outlook - The company is well-positioned in the power grid sector with a diverse product line and a nationwide service network, anticipating continued revenue growth [3]. - Profitability in new sectors is expected to improve gradually, leading to revised net profit forecasts for 2025 and 2026 at 266 million yuan and 316 million yuan respectively, with a new estimate for 2027 at 359 million yuan [3].